new york  reuters    u s  house democrats said on thursday they were launching an investigation into why prices for multiple sclerosis  ms  treatments have nearly quintupled since   and they sent letters requesting information from seven drugmakers   u s  representatives elijah cummings and peter welch sent the letters to bayer ag  biogen inc  merck kgaa s emd serono unit  novartis ag  roche holding ag  sanofi sa  and teva pharmaceutical industries inc  the lawmakers on the u s  house committee on oversight and government reform said in the letters that they were looking to determine whether drug companies were raising prices for ms drugs in lockstep with their competitors  the average annual cost of ms therapy rose to    in  from    in   according to the national multiple sclerosis society  drugmakers have faced a global pushback from regulators and lawmakers about high prices   president donald trump has said the companies are  getting away with murder  and has pledged to lower the cost of prescription drugs  he met with representative cummings to discuss the issue in march  previous congressional investigations and hearings into drug pricing practices have had far reaching effects  mylan nv sharply reduced the cost of epipen after the oversight committee began looking into the increases that drove the list price of the life saving allergy treatment to around   a pair   valeant pharmaceuticals international and turing pharmaceuticals have also faced congressional pressure over high prices  roche said it plans to work with the lawmakers to address their questions  and said the industry needs to reverse the trend of sharp increases in ms drug prices  it said its treatment ocrevus is priced around  percent below the current average cost of treatment and does not plan to aggressively raise its price  a bayer spokeswoman said the company had received the letter and planned to reply directly to the congress members  novartis said it was reviewing the letter to determine how to address the request  sanofi did not immediately have a comment on the probe  biogen  emd serono  and teva pharmaceutical industries inc could not immediately be reached for comment 